NAS:SXTP (USA)
Â
Units(1 ord,1 wr & 1 Non Tr)
$
1.08
-0.050 (-4.42%)
10:08 PM EST
Business Description
60 Degrees Pharmaceuticals Inc
NAICS : 541714
SIC : 2834
ISIN : US83006G4010
Share Class Description:
SXTP: Units(1 ord,1 wr & 1 Non Tr)Total Employee Number:
3Description
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 6.78 | |||||
Equity-to-Asset | 0.61 | |||||
Debt-to-Equity | 0.06 | |||||
Debt-to-EBITDA | -0.02 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -21.11 | |||||
Beneish M-Score | -0.34 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -46.3 | |||||
3-Year EBITDA Growth Rate | 50.9 | |||||
3-Year EPS without NRI Growth Rate | 63.7 | |||||
3-Year FCF Growth Rate | 39 | |||||
3-Year Book Growth Rate | 82.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 68.7 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 21.05 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 36.15 | |||||
9-Day RSI | 35.74 | |||||
14-Day RSI | 35.8 | |||||
3-1 Month Momentum % | -1.33 | |||||
6-1 Month Momentum % | -50 | |||||
12-1 Month Momentum % | -70.87 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.32 | |||||
Quick Ratio | 1.78 | |||||
Cash Ratio | 0.64 | |||||
Days Inventory | 307.66 | |||||
Days Sales Outstanding | 156.51 | |||||
Days Payable | 527.07 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -269.8 | |||||
Shareholder Yield % | -204 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 19.44 | |||||
Operating Margin % | -774.89 | |||||
Net Margin % | -729.88 | |||||
EBITDA Margin % | -720.25 | |||||
FCF Margin % | -815.66 | |||||
OCF Margin % | -789.83 | |||||
ROE % | -228.24 | |||||
ROA % | -148.61 | |||||
ROIC % | -485.11 | |||||
3-Year ROIIC % | 28.93 | |||||
ROC (Joel Greenblatt) % | -797.52 | |||||
ROCE % | -224.28 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 1.18 | |||||
EV-to-EBIT | -1.53 | |||||
EV-to-Forward-EBIT | -1.31 | |||||
EV-to-EBITDA | -1.55 | |||||
EV-to-Forward-EBITDA | -1.31 | |||||
EV-to-Revenue | 11.17 | |||||
EV-to-Forward-Revenue | 12.67 | |||||
EV-to-FCF | -1.37 | |||||
Price-to-GF-Value | 0.8 | |||||
Earnings Yield (Greenblatt) % | -65.36 | |||||
FCF Yield % | -238.47 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SXTP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
60 Degrees Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.111 | ||
| EPS (TTM) ($) | -5.938 | ||
| Beta | 2.6748 | ||
| 3-Year Sharpe Ratio | -0.94 | ||
| 3-Year Sortino Ratio | -1.21 | ||
| Volatility % | 139.57 | ||
| 14-Day RSI | 35.8 | ||
| 14-Day ATR ($) | 0.113198 | ||
| 20-Day SMA ($) | 1.14725 | ||
| 12-1 Month Momentum % | -70.87 | ||
| 52-Week Range ($) | 1.01 - 8.62 | ||
| Shares Outstanding (Mil) | 3.52 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
60 Degrees Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
60 Degrees Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 78 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | 1.18 (-1.67%) | ||
| General meeting for 2026 | 2026-08-05 12:00 | 1.23 (+8.85%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 1.46 (+0.69%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-31 | 1.51 (+4.86%) | ||
| Annual report for 2025 | 2026-03-30 | 1.50 (+2.74%) | ||
| 0.25:1 Stock Split | 2026-01-20 | 2.44 (+25.70%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 4.92 (+0.82%) | ||
| General meeting for 2025 | 2025-10-08 12:00 | 5.80 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-13 | 5.40 (+0.75%) |
Show
Entries
60 Degrees Pharmaceuticals Inc Frequently Asked Questions
What is 60 Degrees Pharmaceuticals Inc(SXTP)'s stock price today?
The current price of SXTP is $1.08. The 52 week high of SXTP is $8.62 and 52 week low is $1.01.
When is next earnings date of 60 Degrees Pharmaceuticals Inc(SXTP)?
The next earnings date of 60 Degrees Pharmaceuticals Inc(SXTP) is 2026-11-13 Est..
Does 60 Degrees Pharmaceuticals Inc(SXTP) pay dividends? If so, how much?
60 Degrees Pharmaceuticals Inc(SXTP) does not pay dividend.
Press Release
Articles on 60 Degrees Pharmaceuticals Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers